RU93032613A - PHARMACEUTICAL PREPARATION FOR THE TREATMENT OF PATIENTS WITH PROLONGED COAGULATION TIME, METHOD OF TREATING PATIENTS, USING THE EPI INHIBITOR FOR OBTAINING THE PHARMACEUTICAL PREPARATION - Google Patents

PHARMACEUTICAL PREPARATION FOR THE TREATMENT OF PATIENTS WITH PROLONGED COAGULATION TIME, METHOD OF TREATING PATIENTS, USING THE EPI INHIBITOR FOR OBTAINING THE PHARMACEUTICAL PREPARATION

Info

Publication number
RU93032613A
RU93032613A RU93032613/14A RU93032613A RU93032613A RU 93032613 A RU93032613 A RU 93032613A RU 93032613/14 A RU93032613/14 A RU 93032613/14A RU 93032613 A RU93032613 A RU 93032613A RU 93032613 A RU93032613 A RU 93032613A
Authority
RU
Russia
Prior art keywords
pharmaceutical preparation
patients
obtaining
treatment
coagulation time
Prior art date
Application number
RU93032613/14A
Other languages
Russian (ru)
Other versions
RU2127600C1 (en
Inventor
Нордфанг Оле
Хеднер Улла
Петер Хунахль Меллер Нильс
Original Assignee
Ново Нордиск А/С
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DK261490A external-priority patent/DK261490D0/en
Application filed by Ново Нордиск А/С filed Critical Ново Нордиск А/С
Publication of RU93032613A publication Critical patent/RU93032613A/en
Application granted granted Critical
Publication of RU2127600C1 publication Critical patent/RU2127600C1/en

Links

Claims (1)

Фармацевтический препарат, содержащий в качестве активного компонента агент, который блокирует EPI-активность (ЕРI-ингибитор), является препаратом с пролонгированным временем коагуляции.A pharmaceutical preparation containing as an active ingredient an agent that blocks the EPI activity (an EPI inhibitor) is a drug with a prolonged coagulation time.
RU93032613A 1990-10-31 1991-10-18 Pharmaceutical preparation that is able to accelerate blood coagulation process, a method of blood coagulation acceleration in vitro, use of an inhibitor of epi-activity as a substance accelerating blood coagulation process RU2127600C1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DK261490A DK261490D0 (en) 1990-10-31 1990-10-31 NEW PHARMACEUTICAL COMPOUND
DK2614/90 1990-10-31
PCT/DK1991/000317 WO1992007584A1 (en) 1990-10-31 1991-10-18 Pharmaceutical preparation for the treatment of prolonged coagulation time

Publications (2)

Publication Number Publication Date
RU93032613A true RU93032613A (en) 1996-06-20
RU2127600C1 RU2127600C1 (en) 1999-03-20

Family

ID=8113744

Family Applications (1)

Application Number Title Priority Date Filing Date
RU93032613A RU2127600C1 (en) 1990-10-31 1991-10-18 Pharmaceutical preparation that is able to accelerate blood coagulation process, a method of blood coagulation acceleration in vitro, use of an inhibitor of epi-activity as a substance accelerating blood coagulation process

Country Status (15)

Country Link
EP (1) EP0558529B1 (en)
JP (1) JPH06502171A (en)
AT (1) ATE132757T1 (en)
AU (1) AU657926B2 (en)
CA (1) CA2095356A1 (en)
CZ (1) CZ282497B6 (en)
DE (1) DE69116380T2 (en)
DK (2) DK261490D0 (en)
ES (1) ES2083597T3 (en)
GR (1) GR3019514T3 (en)
HU (1) HUT64236A (en)
RU (1) RU2127600C1 (en)
SK (1) SK282516B6 (en)
UA (1) UA35567C2 (en)
WO (1) WO1992007584A1 (en)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6063764A (en) * 1992-06-01 2000-05-16 Washington University & Chiron Corp. Method for using lipoprotein associated coagulation inhibitor to treat sepsis
US20030171292A1 (en) 1992-06-01 2003-09-11 Creasey Abla A. Method for using lipoprotein associated coagulation inhibitor to treat sepsis
GB2268909B (en) * 1992-07-21 1995-10-25 Profy International Corp Unitary loose sheet binder
DE60112429T2 (en) * 2000-05-10 2006-06-01 Novo Nordisk Health Care Ag USE OF FACTOR VII-A AND FACTOR XIII-CONTAINING PHARMACEUTICAL COMPOUNDS
US7015194B2 (en) 2000-05-10 2006-03-21 Novo Nordisk A/S Pharmaceutical composition comprising factor VIIa and anti-TFPI
HUP0501111A2 (en) 2001-10-15 2007-12-28 Chiron Corp Treatment of severe pneumonia by administration of tissue factor pathway inhibitor
WO2007014749A2 (en) * 2005-07-29 2007-02-08 Universiteit Van Maastricht Regulation of tissue factor activity by protein s and tissue factor pathway inhibitor
BRPI0914916A2 (en) 2008-06-30 2015-10-20 Novo Nordisk As interleukin-20 antibodies and their method of production
UA112050C2 (en) * 2008-08-04 2016-07-25 БАЄР ХЕЛСКЕР ЛЛСі THERAPEUTIC COMPOSITION CONTAINING MONOCLONAL ANTIBODY AGAINST TISSUE FACTOR INHIBITOR (TFPI)
JP5739816B2 (en) 2008-12-19 2015-06-24 バクスター・インターナショナル・インコーポレイテッドＢａｘｔｅｒ Ｉｎｔｅｒｎａｔｉｏｎａｌ Ｉｎｃｏｒｐ０Ｒａｔｅｄ TFPI inhibitors and methods of use
PL2379600T5 (en) * 2008-12-22 2021-03-08 Novo Nordisk A/S Antibodies against tissue factor pathway inhibitor
US8454956B2 (en) 2009-08-31 2013-06-04 National Cheng Kung University Methods for treating rheumatoid arthritis and osteoporosis with anti-IL-20 antibodies
CN107693791B (en) * 2010-02-26 2022-06-07 诺沃—诺迪斯克有限公司 Compositions comprising stable antibodies
KR101807894B1 (en) 2010-03-01 2017-12-12 바이엘 헬스케어 엘엘씨 Optimized monoclonal antibodies against tissue factor pathway inhibitor (tfpi)
NZ603028A (en) 2010-03-19 2014-11-28 Baxter Healthcare Sa Tfpi inhibitors and methods of use
AU2011257219B2 (en) 2010-05-28 2014-12-04 Novo Nordisk A/S Stable multi-dose compositions comprising an antibody and a preservative
US9228022B2 (en) 2010-06-30 2016-01-05 Novo Nordisk A/S Antibodies that are capable of specifically binding tissue factor pathway inhibitor
TW201212938A (en) 2010-06-30 2012-04-01 Novo Nordisk As Antibodies that are capable of specifically binding tissue factor pathway inhibitor
KR102263685B1 (en) 2012-03-21 2021-06-11 다케다 야쿠힌 고교 가부시키가이샤 Tfpi inhibitors and methods of use
US9221904B2 (en) 2012-07-19 2015-12-29 National Cheng Kung University Treatment of osteoarthritis using IL-20 antagonists
US8603470B1 (en) 2012-08-07 2013-12-10 National Cheng Kung University Use of IL-20 antagonists for treating liver diseases
US8852588B2 (en) 2012-08-07 2014-10-07 National Cheng Kung University Treating allergic airway disorders using anti-IL-20 receptor antibodies

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL87172A (en) * 1987-07-23 1994-12-29 Univ Washington Method of isolating highly purified tissue factor inhibitor
IL87171A (en) * 1987-11-23 1995-08-31 Monsanto Co cDNA of human tissue factor inhibitor
AU617795B2 (en) 1988-03-17 1991-12-05 Leukotech A/S Heparin-binding proteins, dna coding for them, processes for producing them as well as therapeutic preparations containing them
DK148890D0 (en) * 1990-06-19 1990-06-19 Novo Nordisk As PHARMACEUTICAL PREPARATION

Similar Documents

Publication Publication Date Title
RU93032613A (en) PHARMACEUTICAL PREPARATION FOR THE TREATMENT OF PATIENTS WITH PROLONGED COAGULATION TIME, METHOD OF TREATING PATIENTS, USING THE EPI INHIBITOR FOR OBTAINING THE PHARMACEUTICAL PREPARATION
EE02971B1 (en) Use of droloxyfene or its salts in the manufacture of a medicament for the treatment of bone diseases
DE69116380D1 (en) PHARMACEUTICAL PREPARATION FOR TREATING EXTENDED COAGLING TIME
DE3382641D1 (en) MEDICINAL PRODUCTS FOR THE TREATMENT OF ALOPEZIA.
DE69327432D1 (en) MEDICINE FOR Wounds and Hemorrhoid
DE69602412D1 (en) Ophthalmic preparation for the treatment or prevention of dry eye and diseases caused thereby, containing 12-sulfodehydroabietic acid
DK164441C (en) USE OF A PIPERIDE INGREDIENT FOR THE PREPARATION OF A PHARMACEUTICAL PREPARATION FOR THE TREATMENT OF PAIN
DK0668077T3 (en) Products containing G-CSF and TNF-binding protein
NO883750D0 (en) PROCEDURE FOR THE PREPARATION OF THERAPEUTIC ACTIVE PIPERIDE INGREDIENTS.
NO883122L (en) PROCEDURE FOR THE PREPARATION OF THERAPEUTIC ACTIVE ARYLAMIDE DERIVATIVES.
BG60101B2 (en) Method for preparing of 4-fluoro-2-[[(4-methoxy-2-pyridinyl)methyl]thionil]-1h-benzimidazo le
EP0328924A3 (en) Thienotriazolodiazepine compounds and pharmaceutical uses thereof
RU2001118854A (en) OPTICALLY ACTIVE DERIVATIVE OF Pyridyl-4H-1,2,4-Oxadiazine AND ITS APPLICATION FOR TREATMENT OF VASCULAR DISEASES
IT8448983A0 (en) ACTIVE PHARMACEUTICAL AGENT FOR THE TREATMENT OF URIDINE-BASED BRAIN DISEASES
IT1245717B (en) PHARMACEUTICAL COMPOUND BASED ON AN ANTOCYANIDINE FOR THE TREATMENT OF OPHTHALMIC DISEASES
GR3032224T3 (en) Therapeutic agent for threatened abortion.
DE68901172D1 (en) (-) - 2-PYRAZOLINE COMPOUND, THEIR OPTICAL UNLOCKING AND THERAPEUTIC AGENT FOR THE TREATMENT OF CEREBRAL VEGETABLE DISEASES, CONTAINING THIS COMPOUND AS AN ACTIVE INGREDIENT.
NO893256D0 (en) PROCEDURE FOR THE PREPARATION OF FURYLTIAZOLD DERIVATIVES.
DE68905076D1 (en) PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF SKIN Wounds.
ATE131729T1 (en) 3,5-DIIOD-L-THYRONINE FOR TSH SUPPRESSION AND TREATMENT OF STRUMA
WO1986006960A3 (en) Use of nicorandil or pinacidil for the treatment of peripheral vascular disease
ATE12649T1 (en) OPTICALLY ACTIVE DIPEPTIDE, ITS PHARMACEUTICALLY ACCEPTABLE SALTS, METHOD OF PREPARATION AND PHARMACEUTICAL PREPARATIONS CONTAINING THEM.
NO880639D0 (en) PROCEDURE FOR THE PREPARATION OF THERAPEUTIC ACTIVE OXIMETERS OF 2,6-DIOKSABICYCLO (3, 3, 0) OCTANONS.
UA30143A (en) MEDICAL DRUG FOR PREVENTION AND TREATMENT OF INFECTIOUS AND INFLAMMATORY DISEASES
KR927003530A (en) Use of local anesthetics in the manufacture of pharmaceutical formulations for iontophoresis